Effectiveness and Safety of Montelukast as an Adjuvant Therapy to Isotretinoin Treatment of Acne Vulgaris: A Randomized Controlled Trial
Main Article Content
Keywords
acne, Acne Vulgaris, isotretinoin, montelukast
Abstract
Introduction Isotretinoin effectively targets all acne-related pathological mechanisms but is associated with various side effects. On the other hand, montelukast serves as an antagonist to LB4, which is an important mediator in acne pathogenesis.
Objectives This study aimed to compare the efficacy of montelukast as an adjuvant treatment to isotretinoin versus isotretinoin alone for moderate acne vulgaris and to evaluate treatment tolerability by monitoring side effects.
Materials and Methods A randomized comparative prospective trial included 40 patients from the Dermatology and Venereology Hospital at Damascus University. They were assigned into two groups: group A received montelukast (10mg/day) with isotretinoin (20 mg/day for 10 days, followed by 0.6 mg/kg/day for three months), while group B received isotretinoin alone (20 mg/day for 10 days, followed by 0.6 mg/kg/day for three months). Follow-ups occurred on the 40th day and then monthly, assessing GAGS, comedones, inflammatory lesions, total lesions, and side effects at each visit. Additionally, patient satisfaction was assessed during the final visit.
Results Adding montelukast to isotretinoin significantly reduced GAGS, comedones, inflammatory lesions, and total lesions, with statistically significant differences between the beginning and end of treatment. By evaluating patients at the end of treatment period, there were significant statistical differences between the two treatment groups regarding GAGS, inflammatory lesions, total lesions, and patient satisfaction, with more side effects reported in the isotretinoin group.
Conclusion Montelukast combined with isotretinoin is an effective treatment for moderate acne vulgaris, outperforming isotretinoin alone with fewer side effects.
References
2. Vasam M, Korutla S, Bohara RA. Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances. Biochem Biophys Rep. 2023;36:101578. Published 2023 Nov 23. doi:10.1016/j.bbrep.2023.101578.
3. Adah R, Yusufu H, Otene QV. Epidemiology and Perception of Acne Among Adolescents in Jos, Nigeria: Cross-Sectional School-Based Study. JMIR Dermatol. 2023;6:e44441. Published 2023 Jul 12. doi:10.2196/44441.
4. Kim HJ, Kim YH. Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies. Int J Mol Sci. 2024;25(10):5302. Published 2024 May 13. doi:10.3390/ijms25105302.
5. Retinoids. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; November 10, 2020. https://pubmed.ncbi.nlm.nih.gov/31643883.
6. Fox L, Csongradi C, Aucamp M, et al. Treatment Modalities for Acne. Molecules. 2016;21(8):1063. Published 2016 Aug 13. doi:10.3390/molecules21081063.
7. Evaristo LSBF, Bagatin E. Use of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort. Sao Paulo Med J. 2019;137(4):363-368. Published 2019 Oct 31. doi:10.1590/1516-3180.2018.054405072019.
8. Bubna AK. Leukotriene Antagonists in Dermatology. Indian J Dermatol. 2021;66(5):575. doi:10.4103/ijd.IJD_557_18.
9. Rokni GR, Mohammadnezhad F, Saeedi M, et al. Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single-blinded, active-controlled trial. J Cosmet Dermatol. 2021;20(11):3580-3585. doi:10.1111/jocd.14462.
10. Behrangi E, Arasteh E, Tavakoli T, et al. Comparing efficacy of Montelukast versus doxycycline in treatment of moderate acne. J Res Med Sci. 2015;20(4):379-382. https://pubmed.ncbi.nlm.nih.gov/26109994.
11. Alsulaimani H, Kokandi A, Khawandanh S, Hamad R. Severity of Acne Vulgaris: Comparison of Two Assessment Methods. Clin Cosmet Investig Dermatol. 2020;13:711-716. Published 2020 Sep 28. doi:10.2147/CCID.S266320.
12. Ramli R, Malik AS, Hani AF, Jamil A. Acne analysis, grading and computational assessment methods: an overview. Skin Res Technol. 2012;18(1):1-14. doi:10.1111/j.1600-0846.2011.00542.x.
13. ASLAM, Memoona, et al. COMPARISON OF ORAL DOXYCYCLINE WITH ORAL MONTELUKAST IN THE TREATMENT OF MODERATE ACNE VULGARIS. Pakistan Armed Forces Medical Journal, 2020, 3: 797. https://pafmj.org/index.php/PAFMJ/article/download/4663/2734
14. MALIK, Ahmed Naveed, et al. Role of Montelukast in the Management of Moderate Inflammatory Acne. Pakistan Armed Forces Medical Journal, 2025, 75: S146. https://pafmj.org/PAFMJ/article/download/12547/6825/138207
15. Fazelzadeh Haghighi N, Dastgheib L, Saki N, et al. Montelukast as an effective adjuvant in the treatment of moderate acne vulgaris. Dermatol Ther. 2022;35(10):e15770. doi:10.1111/dth.15770
16. Paichitrojjana A, Paichitrojjana A. Oral Isotretinoin and Its Uses in Dermatology: A Review. Drug Des Devel Ther. 2023;17:2573-2591. Published 2023 Aug 25. doi:10.2147/DDDT.S427530
17. Lee HE, Chang IK, Lee Y, et al. Effect of antihistamine as an adjuvant treatment of isotretinoin in acne: a randomized, controlled comparative study. J Eur Acad Dermatol Venereol. 2014;28(12):1654-1660. doi:10.1111/jdv.12403
18. Borghi A, Mantovani L, Minghetti S, et al. Acute acne flare following isotretinoin administration: potential protective role of low starting dose. Dermatology. 2009;218(2):178-180. doi:10.1159/000182270
19. National Guideline Alliance (UK). Addition of oral corticosteroids to oral isotretinoin for the treatment of severe inflammatory acne vulgaris: Acne vulgaris: management. London: National Institute for Health and Care Excellence (NICE); June 2021. https://pubmed.ncbi.nlm.nih.gov/34424624/
20. Pile HD, Patel P, Sadiq NM. Isotretinoin. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 4, 2025. https://pubmed.ncbi.nlm.nih.gov/30247824/
21. AlMasoudi RM, Bahaj RK, Kokandi AA. Patients' Awareness of the Ocular Side Effects of Isotretinoin Therapy: A Study From Saudi Arabia. Cureus. 2022;14(4):e24628. Published 2022 Apr 30. doi:10.7759/cureus.24628
22. Özkoca D, Caf N, Alacagöz Yılmaz NN, et al. Skeletal Side Effects of Systemic Isotretinoin Treatment: Do They Depend on Age, Gender, Treatment Duration, Daily Dose and Isotretinoin-Naiveness?. Dermatol Pract Concept. Published online April 1, 2023. doi:10.5826/dpc.1302a121
23. Taheri A, Sabouhi S, Farazmand F. Incidence of low back pain and sacroiliitis in military families with acne vulgaris under isotretinoin therapy. Am J Clin Exp Immunol. 2020;9(2):6-9. Published 2020 Apr 15. https://pubmed.ncbi.nlm.nih.gov/32419981/
24. Gao CQ, Zhou JJ, Tan YY, Tong CJ. Effectiveness of montelukast for uremic pruritus in hemodialysis patients: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(46):e23229. doi:10.1097/MD.0000000000023229
25. Rahman ML, Choudhury AM, Islam MM. Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Med J. 2006;15(1):85-88. doi:10.3329/mmj.v15i1.8
26. Hardas A, Singh N, Mohanty A, Sahu SK. Efficacy of montelukast in preventing seasonal recurrence of vernal keratoconjunctivitis in children. Eye (Lond). 2022;36(5):978-984. doi:10.1038/s41433-021-01484-3
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.